
Opinion|Videos|August 13, 2025
Choosing an Initial Therapy for Alopecia Areata
Key Takeaways
- Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles.
- Breakdown of immune privilege in hair follicles leads to infiltration by cytotoxic T cells, particularly CD8+ T cells.
Panelists discuss how key factors such as disease severity, patient preference, and payer requirements influence the choice of initial therapy for alopecia areata (AA), highlighting which drug classes have the highest and lowest success rates.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Ungar: Which key factors influence your choice of initial therapy for patients with AA?
- Which drug classes do payers initially require in patients recently diagnosed with AA?
- Which therapies have the highest success rate?
- Which therapies have the lowest success rate?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
Ocrelizumab Leads to Lower Hospitalization Rates Compared to Rituximab in MS
5












































